Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Who Are the Type 2 Von Willebrand Disease Patients? Results from Interim Analysis of the French HRQoL Study: Wish-Qol .

Annie Borel-Derlon, MD PhD, Jenny Goudemand, MD PhD, Dominique Desprez, MD, Céline Falaise, Fabienne Genre Volot, MD, Laurent Ardillon, MD, Brigitte Pan-Petesch, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Agnès Veyradier, Sr., MD PhD, Sylvia Von Mackensen

Blood (2018) 132 (Supplement 1): 2468.

https://doi.org/10.1182/blood-2018-99-113289

Published: 2018

Journal Articles

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Annie Borel-Derlon, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Herve Chambost, MD PhD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Yves Gruel, MD PhD, Agnès Veyradier, Sr., MD PhD, Jenny Goudemand, MD PhD, Sylvia Von Mackensen, PhD

Blood (2017) 130 (Supplement 1): 4866.

https://doi.org/10.1182/blood.V130.Suppl_1.4866.4866

Published: 2017

Journal Articles

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Blood (2016) 128 (22): 327.

https://doi.org/10.1182/blood.V128.22.327.327

Published: 2016

Journal Articles

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

Annie Borel-Derlon, MD PhD, Jenny Goudemand, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Yves Gruel, MD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Agnes Veyradier, MD PhD, Edith Fressinaud, MD, Sylvia von Mackensen, PhD

Blood (2016) 128 (22): 1395.

https://doi.org/10.1182/blood.V128.22.1395.1395

Published: 2016

Journal Articles

Acquired Von Willebrand Syndrome Associated with B Cell Chronic Lymphoproliferative Disorders. Results from a Prospective Observational Study

Jean Baptiste Rabec, MD, Philippe Gautier, MD, Xavier Troussard, MD PhD, Anne Claire Gac, MD, Sylvain Chantepie, MD, Margareth Macro, MD, Stephane Cheze, MD, Khaled Benabed, MD, Damaj Gandhi, MDPhD, Annie Borel Derlon, MDPhD, Yohann Repesse, PhD

Blood (2014) 124 (21): 1509.

https://doi.org/10.1182/blood.V124.21.1509.1509

Published: 2014

Journal Articles

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status

Julie Rayes, Lubka T. Roumenina, Jordan D. Dimitrov, Yohann Repessé, Mathieu Ing, Olivier Christophe, T. Sakari Jokiranta, Lise Halbwachs-Mecarelli, Annie Borel-Derlon, Srinivas V. Kaveri, Véronique Frémeaux-Bacchi, Sébastien Lacroix-Desmazes

Blood (2014) 123 (1): 121–125.

https://doi.org/10.1182/blood-2013-04-495853

Published: 2014

Includes: Supplemental data

Journal Articles

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Catherine Boyer-Neumann, Annie Borel-Derlon, MD, PhD, Jenny Goudemand, MD, PhD, Ségolène Claeyssens, Pierre-Marie Sie, MD, PhD, Philippe Moreau, Marie-Anne Bertrand, MD, Chantal Rothschild, MD, Benoît Guillet, MD, PhD, Jeanne Yvonne Borg, Catherine Chatelanaz, Wil Stevens, Françoise Bridey, Celine Henriet

Blood (2012) 120 (21): 3375.

https://doi.org/10.1182/blood.V120.21.3375.3375

Published: 2012

Journal Articles

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Yohann Repesse, PhD, Ivan Peyron, Jordan Dimitrov, PhD, Suryasarathi Dasgupta, PhD, Elika Farrokhi Moshai, Annie Borel-Derlon, MD, PhD, Catherine Costa, MD, Benoist Guillet, MD, PhD, Roseline d'Oiron, MD, Achille Aouba, MD, Chantal Rothschild, MD, Johannes Oldenburg, MD, Ana Pavlova, MD, Srinivas Kaveri, D. V. M., Ph.D, Sebastien Lacroix-Desmazes, PhD

Blood (2012) 120 (21): 38.

https://doi.org/10.1182/blood.V120.21.38.38

Published: 2012

Journal Articles

Clinical Use of a Von Willebrand Factor with a Low FVIII Content in Von Willebrand Disease Patients Undergoing Surgical Procedures or Deliveries: Results From 5 Prospective Multicenter Studies

Annie Borel-Derlon, MD, PhD, Augusto B. Federici, MD, Jenny Goudemand, MD, PhD, Catherine Chatelanaz, Celine Henriet, Françoise Bridey

Blood (2011) 118 (21): 383.

https://doi.org/10.1182/blood.V118.21.383.383

Published: 2011

Journal Articles

Presence and Evolution of a Catalytic Activity in Patients with Severe, Mild or Moderate Hemophilia A

Sandrine Grosbois, PhD, Marie François-Brionne, Elise Vallée, Philippe Gautier, MD, Yohann Repesse, PhD, Annie Borel-Derlon, MD, PhD

Blood (2011) 118 (21): 1211.

https://doi.org/10.1182/blood.V118.21.1211.1211

Published: 2011

Journal Articles

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Roseline d'Oiron, MD, Virginie Demiguel, MSc, Annie Borel-Derlon, MD, PhD, Ségolène Donadel-Claeyssens, MD, PhD, Jenny Goudemand, MD, PhD, Benoît Guillet, MD, PhD, Yves Gruel, MD, PhD, Valérie Roussel-Robert, MD, Fabienne Volot, MD, Thierry Calvez, MD, MSc

Blood (2011) 118 (21): 1213.

https://doi.org/10.1182/blood.V118.21.1213.1213

Published: 2011

Journal Articles

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Bharath Wootla, Olivier D. Christophe, Ankit Mahendra, Jordan D. Dimitrov, Yohann Repessé, Véronique Ollivier, Alain Friboulet, Annie Borel-Derlon, Hervé Levesque, Jeanne-Yvonne Borg, Sebastien Andre, Jagadeesh Bayry, Thierry Calvez, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes

Blood (2011) 117 (7): 2257–2264.

https://doi.org/10.1182/blood-2010-07-296103

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibitor Development In Patients with Mild and Moderate Hemophilia A: Results From a Single Centre.

Yohann Repesse, Philippe Gautier, Annie Borel-Derlon, MD, PhD

Blood (2010) 116 (21): 1407.

https://doi.org/10.1182/blood.V116.21.1407.1407

Published: 2010

Journal Articles

French Multicenter Study for Post-Marketing Survey of WILFACTIN®: A Von Willebrand Factor Concentrate with a Low FVIII Content.

Annie Borel-Derlon, Jenny Goudemand, Chantal Rothschild, Catherine Chatelanaz, Françoise Bridey, French Post-Marketing Study Group5

Blood (2006) 108 (11): 4052.

https://doi.org/10.1182/blood.V108.11.4052.4052

Published: 2006

Journal Articles

Von Willebrand Factor Protects Factor VIII from Endocytosis by Human Monocytes−Derived Dendritic Cells and Subsequent Presentation to Immune Effectors.

Yohann Repesse, Suryasarathi Dasgupta, Ana Maria Navarette, Sandrine Delignat, Bharath Wootla, Annie Borel-Derlon, Srinivas V. Kaveri, Sebastien Lacroix-Desmazes

Blood (2006) 108 (11): 761.

https://doi.org/10.1182/blood.V108.11.761.761

Published: 2006

Journal Articles

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

Suryasarathi Dasgupta, Yohann Repessé, Jagadeesh Bayry, Ana-Maria Navarrete, Bharath Wootla, Sandrine Delignat, Theano Irinopoulou, Caroline Kamaté, Jean-Marie Saint-Remy, Marc Jacquemin, Peter J. Lenting, Annie Borel-Derlon, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes

Blood (2006) 109 (2): 610–612.

https://doi.org/10.1182/blood-2006-05-022756

Published: 2006

Includes: Supplemental data

Journal Articles

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, Christine Vinciguerrat, Thierry Lambert, Hervé Chambost, Annie Borel-Derlon, Ségolène Claeyssens, Yves Laurian, Thierry Calvez, the members of the FVIII-LFB and Recombinant FVIII study groups

Blood (2006) 107 (1): 46–51.

https://doi.org/10.1182/blood-2005-04-1371

Published: 2006

Journal Articles

Prophylactic Use of rFVIIa in a Young Hemophilia A Patient with Factor VIII Inhibitor.

Annie Borel-Derlon, MD, PhD, Mounia Slaoui, MD, Philippe Gautier, MD, Patricia Guillon

Blood (2005) 106 (11): 4068.

https://doi.org/10.1182/blood.V106.11.4068.4068

Published: 2005

Journal Articles

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Roseline d’Oiron, Jean Maurice Lavergne, Jenny Goudemand, Annie Borel-Derlon, Claude Guerois, Chantal Rothschild, Kathelijne Peerlinck, Herve Chambost, Natalie Stieltjes, the Belgian French MHAI Study Group

Blood (2004) 104 (11): 3088.

https://doi.org/10.1182/blood.V104.11.3088.3088

Published: 2004

Journal Articles

Haemophilia A Genotype and Inhibitor Risk: Preliminary Results of a French Haemophilia Centre.

Annie Borel-Derlon, Mounia Slaoui, Jean Marc Costa, Jean Maurice Lavergne

Blood (2004) 104 (11): 3982.

https://doi.org/10.1182/blood.V104.11.3982.3982

Published: 2004

NARROW

Who Are the Type 2 Von Willebrand Disease Patients? Results from Interim Analysis of the French HRQoL Study: Wish-Qol .

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

Acquired Von Willebrand Syndrome Associated with B Cell Chronic Lymphoproliferative Disorders. Results from a Prospective Observational Study

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Clinical Use of a Von Willebrand Factor with a Low FVIII Content in Von Willebrand Disease Patients Undergoing Surgical Procedures or Deliveries: Results From 5 Prospective Multicenter Studies

Presence and Evolution of a Catalytic Activity in Patients with Severe, Mild or Moderate Hemophilia A

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Inhibitor Development In Patients with Mild and Moderate Hemophilia A: Results From a Single Centre.

French Multicenter Study for Post-Marketing Survey of WILFACTIN®: A Von Willebrand Factor Concentrate with a Low FVIII Content.

Von Willebrand Factor Protects Factor VIII from Endocytosis by Human Monocytes−Derived Dendritic Cells and Subsequent Presentation to Immune Effectors.

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Prophylactic Use of rFVIIa in a Young Hemophilia A Patient with Factor VIII Inhibitor.

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Haemophilia A Genotype and Inhibitor Risk: Preliminary Results of a French Haemophilia Centre.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only